You are here: Industry Insights > Treg

News List

Quell raises $156m Series B funds to develop cell therapies Pharmaceutical-Business-Review
November 30, 2021
Quell Therapeutics has raised $156m funding through an oversubscribed Series B funding round to advance its multi-modular engineered T regulatory (Treg) cell therapy pipeline and platform.
GentiBio raises $157m to develop Treg therapies for autoimmune diseases pharmaceutical-technology
August 13, 2021
GentiBio has raised $157m in a Series A funding round led by Matrix Capital Management to progress its new pipeline of engineered regulatory T cell (Treg) treatments in immunology.
New breakthrough to help immune systems in the fight against cancer prnewswire
July 28, 2021
New research has identified potential treatment that could improve the human immune system's ability to search out and destroy cancer cells within the body.
Iontas and Fair Journey Biologics Partner with Quell Therapeutics contractpharma
March 10, 2021
Novel target binders from Iontas/FJB will be used to uncover functional antibodies to advance Quell’s engineered Treg cell therapy pipeline.
Roche pays €70M upfront for Tusk’s preclinical Treg depleter fiercebiotech
September 29, 2018
Roche has paid €70 million ($81 million) upfront to buy Tusk Therapeutics. The takeover gives Roche control of an anti-CD25 antibody that depleted levels of regulatory T cells (Tregs) in preclinical tests.